![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
No Clinically Significant Interaction of MK-8408 With the HIV Medications Dolutegravir, Raltegravir, Rilpivirine, and Tenofovir Disoproxil Fumarate
|
|
|
Reported by Jules Levin
The 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy
Washington, DC June 8-10, 2016
Wei Gao; Jennifer Talaty; Leticia Arrington; Graig Garrett; William L. Marshall; Nancy Kim*; Eugene E. Marcantonio *Corresponding author
Merck & Co., Inc., Kenilworth, NJ, USA
![HCV1](../images/061616/061616-1/HCV1.gif)
![HCV2](../images/061616/061616-1/HCV2.gif)
![HCV3](../images/061616/061616-1/HCV3.gif)
![HCV4](../images/061616/061616-1/HCV4.gif)
![HCV5](../images/061616/061616-1/HCV5.gif)
![HCV6](../images/061616/061616-1/HCV6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|